Capital Square’s Organogenesis Holdings ORGO Stock Holding History

Capital Square’s Portfolio ORGO Stock Details ORGO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$44.9K	Buy	19,113 +8,305	+77%	+$28.8K	0.02%	221
2025 Q4	$56K	Sell	10,808 -6,202	-36%	-$30.1K	0.03%	210
2025 Q3	$71.8K	Sell	17,010 -5,490	-24%	-$25.5K	0.04%	199
2025 Q2	$96.8K	Sell	22,500 -600	-3%	-$2.24K	0.05%	186
2025 Q1	$99.8K	Buy	23,100 +500	+2%	+$2.02K	0.06%	175
2024 Q4	$80.5K	Buy	22,600 +2,000	+10%	+$6.71K	0.05%	174
2024 Q3	$58.9K	Buy	20,600 +300	+1%	+$841	0.04%	155
2024 Q2	$61.3K	Buy	20,300 +50	+0.2%	+$134	0.04%	143
2024 Q1	$57.5K	Sell	20,250 -200	-1%	-$680	0.04%	141
2023 Q4	$83.6K	Buy	20,450 +3,930	+24%	+$11K	0.09%	95
2023 Q3	$38.8K	Buy	+16,520	New	+$52.5K	0.05%	87

Other funds holding ORGO

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

FLAM

First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Capital Square's ORGO Position: Q1 2026 in Review

Capital Square increased its Organogenesis Holdings (ORGO) stake by 77% in Q1 2026, buying an estimated $28.8K and bringing the position to 19,113 shares worth $44.9K. The position accounts for 0.02% of the portfolio, ranked #221.

Capital Square first reported a position in ORGO in Q3 2023 and has held it in 11 quarters since. The position peaked at $99.8K in Q1 2025. 121 funds tracked by Wall St. Rank hold ORGO as of Q1 2026.

Capital Square held 19,113 shares of Organogenesis Holdings worth $44.9K as of Q1 2026.
Capital Square bought 8,305 Organogenesis Holdings shares in Q1 2026, an estimated $28.8K.
Organogenesis Holdings made up 0.02% of Capital Square's portfolio in Q1 2026, its #221 holding.
Capital Square first reported a position in Organogenesis Holdings in Q3 2023 and has held it in 11 quarters since.
Capital Square's Organogenesis Holdings position peaked at $99.8K in Q1 2025.
121 funds tracked by Wall St. Rank held Organogenesis Holdings as of Q1 2026.

Based on Capital Square's 13F filing for Q1 2026, filed 11 May 2026.